Hi there Fangk,
Correct, selling and admin expenses have increased by $4.30m to $12.40m for the half year.
This is no surprise, and has been previously flagged by management, as the increase is attributable to ARX building up their US sales force.
I am expecting the full year sales and admin cost to be around $25m, so a half year figure of $12.40m is on target.
This is basically an investment that will provide high rate of return in future years.
The company will likely be EBITDA positive in 2024.
Good luck
Ann: Aroa Biosurgery Half Yearly Report Update Amendment, page-3
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
57.0¢ |
Change
0.020(3.64%) |
Mkt cap ! $192.7M | |||
| Open | High | Low | Value | Volume |
| 56.0¢ | 57.0¢ | 55.0¢ | $112.5K | 202.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 151766 | 55.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.0¢ | 25203 | 3 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
56.5¢ |
Change
0.020 ( 1.80 %) |
||||
| Open | High | Low | Volume | ||
| 56.0¢ | 57.0¢ | 55.0¢ | 74038 | ||
| Last updated 15.58pm 06/06/2024 ? | |||||
| ARX (ASX) Chart |